A federal judge has ruled that recent mass layoffs at the U.S. Department of Health and Human Services were likely unlawful ...

This discovery could make treatment for an eye disease affecting millions with diabetes more accessible and affordable.

Dr. Celine Gounder joins CBS Mornings to break down the FDA-approved drug Lenacapavir, which is being called the closest step ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Despite recent ASCO and FDA guidance recommending the inclusion of people living with HIV in pivotal cancer trials, nearly 75 ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

The field of HIV treatment has witnessed a significant transformation since the mid-1990s with the introduction of combination antiretroviral therapy ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Lenacapavir has demonstrated enormous potential as a new HIV prevention tool with a 100 per cent efficacy rate and zero ...

The US Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV.

HealthLink talked with a Seattle-based physician about why the newly approved drug could be a game-changer in preventing HIV.